| Name | Title | Contact Details |
|---|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Were a community organization that emphasizes creativity and innovation to fill the gaps in wellness services in the Twin Cities area!
The Girling Difference Girling Health Care of NY is a leading provider of home health and home concierge care services. We provide personalized, professional care for patients in the comfort of their homes. Our services include home companions, skilled...
Immune Pharmaceuticals is developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.
Harendorf Technolgy is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.